Stock CGEN COMPUGEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 15:05:59 17/07/2024 BST 		5-day change 1st Jan Change
676 ILa -2.27% Intraday chart for Compugen Ltd. +6.39% -1.74%
06-27 Transcript : Compugen Ltd. - Special Call
05-30 Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Compugen Ltd. - Special Call
Compugen to Present at Upcoming Antibody Industrial Symposium
PR
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
PR
Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
CI
Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating
MT
Compugen : Reports First Quarter 2024 Results
PU
Transcript : Compugen Ltd., Q1 2024 Earnings Call, May 20, 2024
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M
MT
Compugen: Q1 Earnings Snapshot
AQ
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Compugen Reports First Quarter 2024 Results
PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
PU
Compugen Names David Silberman CFO
MT
Compugen Appoints David Silberman as Chief Financial Officer
PR
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024
CI
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
PU
Compugen to Participate in Two Upcoming Investor Conferences
PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. CGEN Stock
  5. News Compugen Ltd.